Michael Makris/LinkedIn
Apr 17, 2026, 14:43
Michael Makris: Are Rebalancing Agents in Hemophilia Associated with Thrombosis?
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at University of Sheffield, shared a post on LinkedIn about his recent article, published in the Journal of Thrombosis and Haemostasis։
”The PDF of my Forum article on the potential thrombogenicity of the ‘rebalancing’ agents is now available on the Journal of Thrombosis and Haemostasis website.”
Title: How real is the thrombotic risk with the rebalancing agents used to treat hemophilia?
Author: Michael Makris
Other posts featuring Michael Makris on Hemostasis Today.
-
May 14, 2026, 17:17Abhijit D: Reticulocyte Count Methods in Hematology Laboratories
-
May 14, 2026, 16:46Michele Romoli: Neurointerventional Workforce Gaps and Stroke Thrombectomy Access in Europe
-
May 14, 2026, 16:37Reyes Calzada Bau: What It Means to Live with Immune Thrombocytopenia
-
May 14, 2026, 16:34Julia Owens: Improving Acute Stroke Care for Patients Without Timely Intervention
-
May 14, 2026, 16:28Krish Patel։ Opioid Overdose and Heart-Related Deaths in the USA (1999–2023)
-
May 14, 2026, 16:26Carla Goulart Peron: 79th World Health Assembly Momentum for Global Stroke Action
-
May 14, 2026, 16:21Love Preet Kalra: Honored to Present Our Data on Plasma GFAP Measurements for ICH at ESOC 2026
-
May 14, 2026, 16:09Dino Mehic: BDUC and Its Overlap With Inherited and Rare Bleeding Disorders
-
May 14, 2026, 16:06Silvia Escribano Serrat: Flow Cytometric Osmotic Fragility Testing for Diagnosis of Hereditary Spherocytosis